MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Type of Assessment:

The hippo pathway provides novel insights into lung cancer and mesothelioma treatment.

Journal of Cancer Research and Clinical Oncology 2018 August 3 [Link] Liu XL, Zuo R, Ou WB Abstract PURPOSE: Lung cancer and mesothelioma are two types of respiratory disease that have fatal courses and poor prognoses. Although a substantial number of targeted small molecules and antibody drugs have been developed, the 5-year survival rates of […]

Comments Off on The hippo pathway provides novel insights into lung cancer and mesothelioma treatment.

A comparison of asbestos fiber potency and elongate mineral particle (EMP) potency for mesothelioma in humans.

Toxicology and Applied Pharmacology 2018 August 2 [Link] Garabrant DH, Pastula ST Abstract We analyzed the mesothelioma mortality in cohorts of workers exposed to crocidolite, amosite, and chrysotile to estimate asbestos fiber potency for mesothelioma, using the method of Hodgson and Darnton (2000). We relied on the original 17 cohort studies in their analysis, along […]

Comments Off on A comparison of asbestos fiber potency and elongate mineral particle (EMP) potency for mesothelioma in humans.

Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.

Archives of Pathology and Laboratory Medicine 2018 July 30 [Link] Berg KB, Dacic S, Miller C, Cheung S, Churg A Abstract CONTEXT: – The separation of reactive from malignant mesothelial proliferations is often a difficult morphologic problem. There is contradictory information in the literature on whether methylthioadenosine phosphorylase (MTAP) immunohistochemistry can be used for this […]

Comments Off on Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.

A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.

Respiratory Medicine 2018 August [Link] Petrelli F, Ardito R, Conti B, Coinu A, Cabiddu M, Ghilardi M, Borgonovo K, Barni S, Ghidini Ah3>Abstract Malignant plINTRODUCTION: Advanced malignant pleural mesothelioma (MPM) is generally treated with platinum/pemetrexed-based first-line therapy. Once the disease progresses, evidence for the efficacy of palliative treatments is lacking, and platinum re-challenge or single-agent […]

Comments Off on A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.

Dose-Dependent Effect of Red Blood Cells Transfusion on Perioperative and Long-Term Outcomes in Peritoneal Surface Malignancies Treated with Cytoreduction and HIPEC.

Annals of Surgical Oncology 2018 July 26 [Link] Nizri E, Kusamura S, Fallabrino G, Guaglio M, Baratti D, Deraco M Abstract BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are associated with increased red blood cell transfusion (RBT) demand. Although the deleterious effects of RBT are documented in various settings, its effect in this […]

Comments Off on Dose-Dependent Effect of Red Blood Cells Transfusion on Perioperative and Long-Term Outcomes in Peritoneal Surface Malignancies Treated with Cytoreduction and HIPEC.

A Clinical Trial of TumorGlow® to Identify Residual Disease during Pleurectomy and Decortication.

The Annals of Thoracic Surgery 2018 July 17 [Link] Predina JD, Newton AD, Corbett C, Xia L, Shin M, Sulfyok LF, Okusanya OT, Cengel KA, Haas A, Litzky L, Kucharczuk JC, Singhal S Abstract BACKGROUND: Macroscopic complete resection can provide a select group of malignant pleural mesothelioma (MPM) patients improved survival. During resection, differentiating residual […]

Comments Off on A Clinical Trial of TumorGlow® to Identify Residual Disease during Pleurectomy and Decortication.

Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model.

European Journal of Pharmaceutical Sciences 2018 July 17 [Link] Sonvico F, Barbieri S, Colombo P, Barocelli E, Mucchino C, Cantoni AM, Petronini PG, Rusca M, Carbognani P, Ampoll Abstract Malignant pleural mesothelioma (MPM) is a rare malignancy characterized by a long latency period of 20-50 years after exposure to the main aetiology agent that is asbestos. […]

Comments Off on Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model.

IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.

Human Pathology 2018 July 18 [Link] Hui S, Guo-Qi Z, Xiao-Zhong G, Chun-Rong L, Yu-Fei L, Dong-Liang Y Abstract Malignant peritoneal mesothelioma (MPeM) is an incurable cancer with poor prognosis and several biomarkers have been suggested for screening of MPeM. The aim of our study was to evaluate the prognostic significanceas of IMP3 and Fli-1 […]

Comments Off on IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.

Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts.

Frontiers in Genetics 2018 July 4 [Link] Nabavi N, Wei J, Lin D, Collins CC, Gout PW, Wang Y Abstract Malignant mesothelioma (MM) is a rare disease often associated with environmental exposure to asbestos and other erionite fibers. MM has a long latency period prior to manifestation and a poor prognosis. The survival post-diagnosis is […]

Comments Off on Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts.

Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.

International Journal of Medical Sciences 2018 June 4 [Link] Aguilar-Madrid G, Pesch B, Calderón-Aranda ES, Burek K, Jiménez-Ramírez C, Juárez-Pérez CA, Ochoa-Vázquez MD, Torre-Bouscoulet L, Acosta-Saavedra LC, Sada-Ovalle I, García-Figueroa J, Alvarado-Cabrero I, Castillo-González P, Báez-Saldaña AR, Pérez-Padilla JR, Osnaya-Juárez J, Rivera-Rosales RM, García-Bazán EM, Bautista-Aragón YL, Lazcano-Hernandez E, Munguía-Canales DA, Argote-Greene LM, Taeger D, […]

Comments Off on Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.